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Think twice about nebulizers 
for asthma attacks
MDIs with spacers are as effective as nebulizers  
for delivering beta-agonists and less likely to cause 
adverse effects.
PRACTICE CHANGER
Stop ordering nebulizers to deliver beta- 
agonists to patients over age 2 with mild or 
moderate asthma exacerbations. A metered-
dose inhaler (MDI) with a spacer produces 
the same benefits with fewer adverse effects.1
StRENGtH oF RECoMMENDAtioN
A: Based on an updated Cochrane meta-
analysis of 39 randomized controlled trials 
(RCTs).
Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebu-
lisers for beta-agonist treatment of acute asthma. Cochrane Database 
Syst Rev. 2013;9:CD000052.
ILLUSTRATIVE CASE
A 6-year-old girl with a history of reactive 
airway disease comes to your office complain-
ing of cough and wheezing. On exam, she 
has mild retractions, a respiratory rate of 35, 
and an oxygen saturation of 96% on room 
air. Her lung fields are diffusely wheezy. Her 
parents would like to keep her out of the hos-
pital. How should you order her albuterol to 
decrease her wheezing and minimize adverse 
effects?
Asthma affects nearly 19 million adults and 7 million children in the United States.2 Asthma exacerba-
tions are the third most common reason 
for hospitalization in children.2,3 Treatment 
usually requires multiple agents, including 
inhaled beta-agonists. These are most ef-
fective when delivered to the peripheral air-
ways, which is a challenge during an asthma 
exacerbation because of airway swelling and 
rapid breathing. Two devices have been de-
veloped to effectively deliver medication to 
the peripheral airways: nebulizers and MDIs 
with a holding chamber (spacer).1 
Several studies have demonstrated 
that for mild to moderate asthma exacerba-
tions, administering a beta-agonist via an 
MDI with a spacer is as effective as using a 
nebulizer.4,5 Asthma treatment guidelines 
also state that spacers are either compa-
rable to or preferred over nebulizers for be-
ta-agonist administration in children and 
adults.6,7 However, based on our experience, 
physicians still frequently order nebulizer 
treatments for patients with asthma exac-
erbations, despite several advantages of 
MDIs with spacers. Notably, they cost less 
and don’t require maintenance or a power 
source. Physicians administered nebulizer 
therapy at more than 3.6 million emergency 
department (ED) visits in 2006.8 
In this latest Cochrane review, Cates et 
al1 added 4 new studies to those included in 
their earlier Cochrane meta-analysis, and 
looked at what, if any, effect these studies had 
on our understanding of nebulizers vs MDIs 
with spacers.
STUDY SUMMARY
outcomes with nebulizers  
are no better than those with spacers
This systematic review and meta-analysis 
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For what  
percentage of 
patients having a 
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asthma attack do 
you routinely  
order nebulizer 
treatment? 
n  <25%
n  25% to 50%
n 51% to 75%
n  >75%
INsTANT  
POLL
jfponline.com
322 THe jOURNAL OF FAmILy PRAcTIce  |   jUNe 2014  |   VOL 63, NO 6
PURLs®
the time  
children spent in 
the ED was cut 
by about half an 
hour when MDis 
with spacers 
were used.
pooled the results of RCTs comparing spacers 
to nebulizers for administering beta-agonists 
during acute, non-life-threatening asthma 
exacerbations.1 The authors reviewed studies 
conducted in EDs, hospitals, and outpatient 
settings that included children and adults. The 
primary outcomes were hospital admission 
rates and duration of hospital stay. Second-
ary outcomes included time spent  in the ED, 
change in pulse rate, and incidence of tremor.
Cates et al1 analyzed 39 trials that in-
cluded 1897 children and 729 adults and 
were conducted primarily in an ED or out-
patient setting. The 4 new studies added 
295 children and 58 adults to the research-
ers’ earlier meta-analysis. Studies involving 
adults and children were pooled separately. 
Most patients received multiple treatments 
with beta-agonists titrated to the individu-
al’s response. 
z No differences in hospitalizations. 
Rates of hospital admissions did not differ 
between patients receiving beta-agonists via 
a spacer compared to a nebulizer in both 
adults (relative risk [RR]=.94; 95% confidence 
interval [CI], .61-1.43) and children (RR=.71; 
95% CI, .47-1.08). Duration of hospital stay 
did not differ between the 2 delivery methods 
in adults (mean difference [MD]=-.60 days; 
95% CI, -3.23 to 2.03) and children (MD=.33 
days; 95% CI, -.10 to .76). 
z For kids, spacers meant less time 
in the ED. Duration in the ED was approxi-
mately half an hour shorter for children us-
ing spacers (MD=-33.48 minutes; 95% CI, 
-43.3 to -23.6, P<.001). There was no differ-
ence in time spent in the ED observed in 
adults (MD=1.75 minutes; 95% CI, -23.45 to 
26.95). The rate of tremor was lower in chil-
dren using spacers (RR=.64; 95% CI, .44-.95, 
P=.027), and was similar in adults (RR=1.12; 
95% CI, .66-1.9). The rise in pulse rate was 
lower in children using spacers (MD=-5.41% 
change from baseline; 95% CI, -8.34 to -2.48; 
P<.001), and was similar in adults (MD=
-1.23%; 95% CI, -4.06 to 1.60).
WHAT’S NEW
Additional evidence that spacers  
are as effective as nebulizers
This meta-analysis, which included 4 new 
studies, should finally dispel the myth that 
nebulizers deliver beta-agonists more effec-
tively than MDIs with spacers. Additionally, 
in children, spacers are associated with lower 
rates of side effects, including tremor and el-
evated pulse rate.
CAVEATS
Most studies involving children 
were open label
Although most of the adult trials in this meta-
analysis involved a double-dummy design, 
which allows for effective participant blind-
ing, most of the studies involving children 
were open label. This open-label design 
might have been a source of reporting bias 
for symptom-related outcomes, but should 
not have affected hospital admission rates or 
duration of hospital stay.
In the double-dummy studies, adults re-
ceived both a nebulizer and a spacer, which 
likely explains the similar time spent in the 
ED by the treatment and control groups. 
CHALLENGES TO IMPLEMENTATION
old habits are hard to break
Doctors may think that patients view neb-
ulizers as more potent or more effective 
than spacers and thus be more likely to or-
der them. Some patients may prefer nebu-
lizers because of convenience or other 
factors.                  JFP
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